# AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 50% Upside Potential with Analyst Confidence

- Link: https://www.directorstalkinterviews.com/angiodynamics-inc-ango-stock-analysis-exploring-a-50-upside-potential-with-analyst-confidence/4121233182
- Published: 2026-01-02T11:26:35+00:00
- Author: Madison Wilson

AngioDynamics, Inc. (NASDAQ: ANGO), a prominent player in the healthcare sector,
is catching the attention of investors, particularly due to its impressive potential
upside. With a market capitalization of $529.01 million, the company has positioned
itself as a key innovator in the medical instruments and supplies industry, delivering
cutting-edge solutions for peripheral vascular diseases and oncology treatments.

**Current Market Position and Price Dynamics**

As of the latest update, AngioDynamics’ stock is priced at $12.84, reflecting a 
slight decrease of 0.16 points, or 0.01%. The stock has demonstrated resilience,
trading within a 52-week range of $8.37 to $13.64. This stability is further underscored
by its technical indicators, with the 50-day moving average at $12.61 and the 200-
day moving average at $10.56. The Relative Strength Index (RSI) of 70.09 suggests
the stock is nearing overbought territory, indicating robust investor interest.

**Valuation and Performance Insights**

Despite the lack of a trailing P/E ratio and a challenging forward P/E of -81.96,
AngioDynamics has showcased commendable revenue growth of 12.20%. However, the company’s
negative earnings per share (EPS) of -0.78 and a return on equity of -17.10% highlight
areas of financial strain. The absence of positive free cash flow, currently at -
$642,125, suggests ongoing challenges in cash management and profitability.

**Strategic Product Offerings**

AngioDynamics has carved a niche in the medical technology space with its diverse
portfolio, including the Auryon Atherectomy system, AlphaVac mechanical thrombectomy
system, and NanoKnife IRE Ablation System. These innovative products are designed
to improve patient outcomes in vascular and oncology settings, enhancing the company’s
reputation for technological prowess.

**Analyst Ratings and Growth Prospects**

The company enjoys a favorable outlook from analysts, with 3 buy ratings and no 
hold or sell ratings, reflecting strong confidence in its growth trajectory. The
average target price of $19.33 presents a remarkable upside potential of 50.57%,
making it an attractive proposition for growth-oriented investors. The target price
range of $16.00 to $24.00 further underscores the positive sentiment surrounding
AngioDynamics’ future performance.

**Investment Considerations**

While AngioDynamics presents compelling growth opportunities, potential investors
should weigh the inherent risks associated with its current financial metrics. The
absence of dividends and the challenges highlighted by negative EPS and free cash
flow necessitate a cautious approach. However, the company’s innovative product 
line and strong analyst endorsements offer a promising outlook for those willing
to embrace its growth potential.

Investors keen on capitalizing on the healthcare sector’s dynamic landscape may 
find AngioDynamics a noteworthy contender. With its strategic focus on advanced 
medical solutions and the potential for significant stock appreciation, AngioDynamics
stands as a beacon of opportunity amidst the evolving market conditions.

Share on:
